Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approach

The aim of this work was to evaluate whether the treatment effects on magnetic resonance imaging (MRI) markers at the trial level were able to predict the treatment effects on relapse rate in relapsing‐remitting multiple sclerosis.

[1]  Frederik Barkhof,et al.  Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. , 2003, Archives of neurology.

[2]  F. Barkhof.  The clinico‐radiological paradox in multiple sclerosis revisited , 2002, Current opinion in neurology.

[3]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[4]  I. Vavasour,et al.  A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain , 2000, Neurology.

[5]  Seth E. Bouvier,et al.  Comparison of Multiple Sclerosis Lesions at 1.5 and 3.0 Tesla , 2003, Investigative radiology.

[6]  S. Ekholm,et al.  Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis , 1996, Multiple sclerosis.

[7]  S. Reingold,et al.  The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.

[8]  E. Radue,et al.  Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis , 2008, Annals of neurology.

[9]  D. Li,et al.  Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. , 1999, Annals of neurology.

[10]  O. Khan,et al.  INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL , 2009, Neurology.

[11]  M Filippi,et al.  MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b , 2003, Neurology.

[12]  S. Ekholm,et al.  A randomized, double-blind, placebo-controlled MRI study of anti–herpes virus therapy in MS , 2002, Neurology.

[13]  P Flandre,et al.  Estimating the proportion of treatment effect explained by a surrogate marker. , 1999, Statistics in Medicine.

[14]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[15]  Massimo Filippi,et al.  European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.

[16]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[17]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[18]  E. Celius,et al.  Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis. , 1999, Neurology.

[19]  R. Scheyer,et al.  A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses , 2006, Neurology.

[20]  D. Miller,et al.  Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses , 2008, Multiple sclerosis.

[21]  B. Bergamasco,et al.  Chronic systemic high‐dose recombinant interferon alfa‐2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing‐remitting multiple sclerosis , 1994, Neurology.

[22]  Xingchang Wei,et al.  A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta , 2005, Multiple sclerosis.

[23]  L. Kappos,et al.  A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS , 2002, Neurology.

[24]  D. Goodin.  Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment? , 2006, Annals of neurology.

[25]  E. Celius,et al.  Interferon-α2a reduces MRI disease activity in relapsing-remitting multiple sclerosis , 1999, Neurology.

[26]  G. Molenberghs,et al.  Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.

[27]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[28]  C. Pozzilli,et al.  Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome , 1997, Journal of Neurology.

[29]  C. Constantinescu,et al.  Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study , 2008, The Lancet Neurology.

[30]  J S Wolinsky,et al.  EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis , 2006, European journal of neurology.

[31]  Jeanelle Sheeder,et al.  Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis , 1998 .

[32]  J H Simon,et al.  Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. , 1998, Annals of neurology.

[33]  G. Comi,et al.  Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study , 2008, The Lancet.

[34]  D. Paty,et al.  TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study , 1999, Neurology.

[35]  L. Kappos,et al.  Predictors of relapse rate in MS clinical trials , 2005, Neurology.

[36]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[37]  M. Filippi,et al.  MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients , 2002, Neurology.

[38]  W. Engel,et al.  INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL , 2009, Neurology.

[39]  M. van Buchem,et al.  Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[40]  Massimo Filippi,et al.  The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis , 2003, The Lancet Neurology.

[41]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[42]  Jerry S. Wolinsky,et al.  Ingested IFN-α , 2001, Neurology.

[43]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[44]  F Barkhof,et al.  Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. , 2001, Brain : a journal of neurology.

[45]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[46]  Frederik Barkhof,et al.  Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. , 2005, Radiology.

[47]  F. Barkhof,et al.  Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype. , 2001, Brain : a journal of neurology.

[48]  Giuseppe Scotti,et al.  Pyramidal tract lesions and movement-associated cortical recruitment in patients with MS , 2004, NeuroImage.

[49]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[50]  B E Kendall,et al.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. , 1988, Brain : a journal of neurology.

[51]  Massimo Filippi,et al.  Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study , 2006, The Lancet Neurology.

[52]  D. Paty,et al.  Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis , 1999 .

[53]  Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. , 1999, Neurology.

[54]  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. , 1998, Lancet.

[55]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[56]  D. Bourdette,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis , 2008, Current neurology and neuroscience reports.